Supplements

Modified Sini Powder reduces depressive symptoms in postoperative NSCLC patients with mild-to-moderate depression

This protocol describes a multicenter, randomized, double-blind, placebo-controlled trial evaluating Modified Sini Powder (MSNP) for postoperative mild-to-moderate depression in 468 NSCLC patients. The primary outcome is the total effective rate at 6 weeks, defined as a ≥25% reduction in the 17-item Hamilton Depression Rating Scale score from baseline.

1 min read•Updated Jul 7, 2026•1 RCTs•View structured evidence →
Evidence Score42/100
Human RCT★★☆☆☆
Meta-analysis☆☆☆☆☆
Mechanism★★★★★
Safety★★★★☆
Confidencelow

This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.

Modified Sini Powder reduces depressive symptoms in postoperative NSCLC patients with mild-to-moderate depression The current body of evidence comprises 1 study, including 1 randomized controlled trial. EvidenceHub rates the overall confidence at 42/100 (low).

The Claim

Modified Sini Powder reduces depressive symptoms in postoperative NSCLC patients with mild-to-moderate depression

This conclusion is most relevant to: Postoperative patients with non-small cell lung cancer (NSCLC) and mild-to-moderate depression.

What the Research Shows

The conclusion draws on 1 linked study. Highlights from the cited literature:

  • ▸Modified sini powder for the management of postoperative depression in non-small cell lung cancer patients: a multicenter, randomized, double-blind, placebo-controlled trial protocol. (Frontiers in pharmacology, 2026) —

How It Works

The proposed biological pathway:

  • ▸Modulation of inflammatory cytokines
  • ▸Regulation of hypothalamic-pituitary-adrenal axis hormones
  • ▸Alteration of neurotransmitters and brain-derived neurotrophic factor
  • ▸Result: Multi-target and multi-pathway antidepressant effects

Who Might Benefit

Evidence fit by population:

  • ▸Postoperative patients with non-small cell lung cancer (NSCLC) and mild-to-moderate depression

Limitations & Caveats

Important context when interpreting this evidence:

  • ▸This is a protocol paper; no results are reported yet, so efficacy and safety are not established.
  • ▸The trial relies on subjective depression rating scales, which may introduce measurement bias.

Frequently Asked Questions

What is Modified Sini Powder?▼

Modified Sini Powder (MSNP) is a modified traditional Chinese medicine formula derived from classical Sini Powder, used to alleviate depressive symptoms.

How many patients will be in this trial?▼

The trial plans to recruit 468 postoperative NSCLC patients with mild-to-moderate depression across nine tertiary medical centers.

What is the primary outcome of the study?▼

The primary outcome is the total effective rate at the end of 6 weeks of treatment, defined as a ≥25% reduction in the 17-item Hamilton Depression Rating Scale score from baseline.

When was this trial registered?▼

The trial was registered on September 1, 2025, at the International Traditional Medicine Clinical Trial Registration Center (Identifier: ITMCTR2025001642).

References

  1. 1.Jin Y, Wang J, Li H, Fan M, Zhang S, Lin B, Mi Y, Gong C, Gu P, Xu K, Zhao B, Lang J, Chen M. “Modified sini powder for the management of postoperative depression in non-small cell lung cancer patients: a multicenter, randomized, double-blind, placebo-controlled trial protocol..” Frontiers in pharmacology, 2026. PMID: 42403716 DOI: 10.3389/fphar.2026.1805554
Disclaimer: This article is auto-generated from structured research data for educational purposes only and is not medical advice. Evidence scores reflect the quality and quantity of available research, not clinical recommendations. Always consult a healthcare professional before starting any supplement or intervention.